Phase Ib Trial of Multiple-ascending Doses of EMD 1201081 in Combination With 5-FU/Cisplatin and Cetuximab in First-line Subjects With Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck.

Trial Profile

Phase Ib Trial of Multiple-ascending Doses of EMD 1201081 in Combination With 5-FU/Cisplatin and Cetuximab in First-line Subjects With Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2014

At a glance

  • Drugs IMO 2055 (Primary) ; Cetuximab; Cisplatin; Fluorouracil
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck KGaA
  • Most Recent Events

    • 08 Jul 2011 Status changed from recruiting to discontinued.
    • 07 Jul 2011 Merck KGaA terminated this trial due to increased incidence of neutropaenia and electrolyte imbalances.
    • 27 May 2011 Actual initiation date (Aug 2010) added, aditional lead trial investigator (Dr. Jean-Pierre Delord) identified and additional locations (Belgium, France, Germany) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top